Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Lilly

Status and phase: Completed; Phase 2

Conditions: Non-Small-Cell Lung Carcinoma

Treatments: Drug: Enzastaurin HCL

Study type: Interventional

Funder types: Industry

Identifiers

NCT00105092

8670

H6Q-MC-JCAQ

Details and patient eligibility

About

Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must be at least 18 years old
• Must have been diagnosed with advanced or metastatic non-small cell lung cancer
• Must be able to visit the doctor's office every 28 days for 6 months or longer.

Exclusion criteria

• Pregnant or breastfeeding women
• Have other significant medical problems as determined by your physician
• Are unable to swallow tablets
• Have a history of significant heart disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)